BR112012024872A2 - - Google Patents

Info

Publication number
BR112012024872A2
BR112012024872A2 BR112012024872A BR112012024872A BR112012024872A2 BR 112012024872 A2 BR112012024872 A2 BR 112012024872A2 BR 112012024872 A BR112012024872 A BR 112012024872A BR 112012024872 A BR112012024872 A BR 112012024872A BR 112012024872 A2 BR112012024872 A2 BR 112012024872A2
Authority
BR
Brazil
Application number
BR112012024872A
Other languages
Portuguese (pt)
Other versions
BR112012024872B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112012024872A2 publication Critical patent/BR112012024872A2/pt
Publication of BR112012024872B1 publication Critical patent/BR112012024872B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/11Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/145Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112012024872-3A 2010-03-29 2011-03-29 Composições farmacêuticas compreendendo um polipeptídeo contendo pelo menos um motivo cxxc e antígenos heterólogos e seus usos BR112012024872B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305317.9 2010-03-29
EP10305317 2010-03-29
PCT/EP2011/054866 WO2011120994A1 (en) 2010-03-29 2011-03-29 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof

Publications (2)

Publication Number Publication Date
BR112012024872A2 true BR112012024872A2 (US20030162802A1-20030828-C00670.png) 2017-08-15
BR112012024872B1 BR112012024872B1 (pt) 2022-01-11

Family

ID=42312972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024872-3A BR112012024872B1 (pt) 2010-03-29 2011-03-29 Composições farmacêuticas compreendendo um polipeptídeo contendo pelo menos um motivo cxxc e antígenos heterólogos e seus usos

Country Status (12)

Country Link
US (1) US9801927B2 (US20030162802A1-20030828-C00670.png)
EP (2) EP3156068B1 (US20030162802A1-20030828-C00670.png)
JP (1) JP5942296B2 (US20030162802A1-20030828-C00670.png)
KR (1) KR101866301B1 (US20030162802A1-20030828-C00670.png)
CN (1) CN103002909B (US20030162802A1-20030828-C00670.png)
AR (1) AR081809A1 (US20030162802A1-20030828-C00670.png)
BR (1) BR112012024872B1 (US20030162802A1-20030828-C00670.png)
CA (1) CA2792174C (US20030162802A1-20030828-C00670.png)
ES (1) ES2619077T3 (US20030162802A1-20030828-C00670.png)
SG (1) SG183977A1 (US20030162802A1-20030828-C00670.png)
UY (1) UY33297A (US20030162802A1-20030828-C00670.png)
WO (1) WO2011120994A1 (US20030162802A1-20030828-C00670.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2476437B1 (en) 2006-08-11 2018-11-28 Life Sciences Research Partners VZW Immunogenic peptides and their use in immune disorders
CA2715517C (en) * 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in preventing or treating allograft rejection
EP2623124A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
PL2249864T3 (pl) * 2008-02-14 2016-11-30 Strategie zapobiegania i/lub leczenia odpowiedzi immunologicznych na rozpuszczalne alloczynniki
US20120009678A1 (en) 2008-02-14 2012-01-12 Jean-Marie Saint-Remy Immunotherapy targeting intracellular pathogens
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
DK2643345T5 (da) 2010-11-25 2021-05-17 Imnate Sarl Immunogene peptider til anvendelse til forebyggelse og/eller behandling af infektionssygdomme, autoimmune sygdomme, immunresponser på allofaktorer, allergisygdomme, tumorer, transplantatafstødning og immunresponser på virusvektorer anvendt til genterapi eller genvaccination
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US9457096B2 (en) * 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するb型肝炎ウイルス様粒子結晶
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10729791B2 (en) * 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
ES2874077T3 (es) 2015-09-25 2021-11-04 Imcyse Sa Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos
KR20180134935A (ko) 2016-04-19 2018-12-19 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
PE20191529A1 (es) 2017-03-09 2019-10-23 Imcyse Sa Peptidos y metodos para el tratamiento de diabetes
EP4144752A1 (en) * 2021-09-02 2023-03-08 Sorbonne Universite Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165469A (en) * 1988-01-13 2000-12-26 University Of Virginia Recombinant Entamoeba histolytica lectin subunit peptides and reagents specific for members of the 170 kD subunit multigene family
AU775695B2 (en) * 1999-03-12 2004-08-12 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
US7943396B2 (en) * 2004-06-22 2011-05-17 The Regents Of The University Of California Peptide-coated nanoparticles with graded shell compositions
EP1763693B1 (de) 2004-07-02 2009-11-18 Schölly Fiberoptic GmbH Vorrichtung und verwendung der vorrichtung zur aufnahme und verarbeitung eines bildes
WO2006026746A2 (en) 2004-08-31 2006-03-09 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to separate and expand antigen-specific t cells
GB0426641D0 (en) * 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
ES2369608T3 (es) 2006-04-13 2011-12-02 Midatech Ltd. Nanopartículas que contienen tres ligandos diferentes para proporcionar respuestas inmunitarias frente a agentes infecciosos.
CA2659275C (en) 2006-07-27 2017-01-10 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
EP2476437B1 (en) * 2006-08-11 2018-11-28 Life Sciences Research Partners VZW Immunogenic peptides and their use in immune disorders
EP2199301A1 (en) 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof

Also Published As

Publication number Publication date
UY33297A (es) 2011-09-30
CN103002909A (zh) 2013-03-27
CA2792174C (en) 2019-09-24
EP3156068B1 (en) 2021-11-03
EP2552476B1 (en) 2016-12-07
CA2792174A1 (en) 2011-10-06
WO2011120994A1 (en) 2011-10-06
KR101866301B1 (ko) 2018-06-11
BR112012024872B1 (pt) 2022-01-11
EP3156068A1 (en) 2017-04-19
KR20130063497A (ko) 2013-06-14
SG183977A1 (en) 2012-10-30
US20130095133A1 (en) 2013-04-18
ES2619077T3 (es) 2017-06-23
US9801927B2 (en) 2017-10-31
JP5942296B2 (ja) 2016-06-29
JP2013523686A (ja) 2013-06-17
CN103002909B (zh) 2016-06-29
EP2552476A1 (en) 2013-02-06
AR081809A1 (es) 2012-10-24

Similar Documents

Publication Publication Date Title
BR112013013385A2 (US20030162802A1-20030828-C00670.png)
BR112013008959A2 (US20030162802A1-20030828-C00670.png)
BR112012029986A2 (US20030162802A1-20030828-C00670.png)
BR112012026492A2 (US20030162802A1-20030828-C00670.png)
BR112012024897A2 (US20030162802A1-20030828-C00670.png)
BR112012019354A2 (US20030162802A1-20030828-C00670.png)
BR112012025307A2 (US20030162802A1-20030828-C00670.png)
BR112012002126A2 (US20030162802A1-20030828-C00670.png)
BR112012017960A2 (US20030162802A1-20030828-C00670.png)
BR112012025482A2 (US20030162802A1-20030828-C00670.png)
BR112012025577A2 (US20030162802A1-20030828-C00670.png)
BR112012023249A2 (US20030162802A1-20030828-C00670.png)
BR112012016456A2 (US20030162802A1-20030828-C00670.png)
BR112012025308A2 (US20030162802A1-20030828-C00670.png)
BR112012018256A2 (US20030162802A1-20030828-C00670.png)
BR112012023265A2 (US20030162802A1-20030828-C00670.png)
BR112013010949A2 (US20030162802A1-20030828-C00670.png)
BR112012026403A2 (US20030162802A1-20030828-C00670.png)
BR112012022788A2 (US20030162802A1-20030828-C00670.png)
BR112013012726A2 (US20030162802A1-20030828-C00670.png)
BR112012023446A2 (US20030162802A1-20030828-C00670.png)
BR112012016895A2 (US20030162802A1-20030828-C00670.png)
BR112013015388A2 (US20030162802A1-20030828-C00670.png)
BR112013007731A2 (US20030162802A1-20030828-C00670.png)
BR112012023744A2 (US20030162802A1-20030828-C00670.png)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.